Search results for " beta-1"

showing 10 items of 19 documents

An arthritogenic alphavirus uses the α1β1 integrin collagen receptor

2005

Ross River (RR) virus is an alphavirus endemic to Australia and New Guinea and is the aetiological agent of epidemic polyarthritis or RR virus disease. Here we provide evidence that RR virus uses the collagen-binding alpha1beta1 integrin as a cellular receptor. Infection could be inhibited by collagen IV and antibodies specific for the beta1 and alpha1 integrin proteins, and fibroblasts from alpha1-integrin-/- mice were less efficiently infected than wild-type fibroblasts. Soluble alpha1beta1 integrin bound immobilized RR virus, and peptides representing the alpha1beta1 integrin binding-site on collagen IV inhibited virus binding to cells. We speculate that two highly conserved regions with…

α1β1 integrinCollagen Type IVIntegrin alpha1IntegrinAlphavirusBiologyVirus ReplicationAntibodiesVirusIntegrin alpha1beta1Collagen receptorMiceRoss River virusVirologyRoss River virusAnimalsHumansMice KnockoutCollagen IVVirus receptorFibroblastsbiology.organism_classificationMolecular biologySolubilityIntegrin alpha Mbiology.proteinReceptors VirusIntegrin beta 6Receptors Adrenergic beta-1ReceptorHeLa CellsVirology
researchProduct

Diastolic dysfunction and central obesity related hypertension: role of trasforming growth factor beta-1

2004

Abstract P-368 Key Words: Diastolic Dysfunction, Obesity Related Hypertension, Trasforming Growth Factor beta-1

medicine.medical_specialtySettore MED/09 - Medicina InternaMegalencephalic leukoencephalopathy with subcortical cystsmedicine.medical_treatmentDiastoleSettore MED/10 - Malattie Dell'Apparato RespiratorioOverweightLeft ventricular hypertrophyInternal medicineInternal MedicinemedicineSystolebiologybusiness.industryGrowth factorDiastolic Dysfunction Obesity Related Hypertension Trasforming Growth Factor beta-1Transforming growth factor betaDiastolic dysfunction HypertensionTrasforming factor beta 1medicine.diseaseSettore MED/11 - Malattie Dell'Apparato CardiovascolareObesityEndocrinologybiology.proteinCardiologymedicine.symptombusinessAmerican Journal of Hypertension
researchProduct

Oral Palmitoylethanolamide Treatment Is Associated with Reduced Cutaneous Adverse Effects of Interferon-β1a and Circulating Proinflammatory Cytokines…

2016

Palmitoylethanolamide (PEA) is an endogenous lipid mediator known to reduce pain and inflammation. However, only limited clinical studies have evaluated the effects of PEA in neuroinflammatory and neurodegenerative diseases. Multiple sclerosis (MS) is a chronic autoimmune and inflammatory disease of the central nervous system. Although subcutaneous administration of interferon (IFN)-β1a is approved as first-line therapy for the treatment of relapsing–remitting MS (RR-MS), its commonly reported adverse events (AEs) such as pain, myalgia, and erythema at the injection site, deeply affect the quality of life (QoL) of patients with MS. In this randomized, double-blind, placebo-controlled study,…

Male0301 basic medicinemyalgiaErythemaAnti-Inflammatory AgentsPalmitic AcidAdministration OralPharmacologyGastroenterologychemistry.chemical_compound0302 clinical medicineNeuroinflammationFAAHEthanolaminePharmacology (medical)SkinInterleukin-17food and beveragesAnti-Inflammatory AgentTolerabilityEthanolaminesDisease ProgressionCytokinesOriginal ArticleFemalemedicine.symptomInterferon beta-1aHumanAdultmedicine.medical_specialtyPainPalmitic AcidsProinflammatory cytokineInterferon-gamma03 medical and health sciencesMultiple Sclerosis Relapsing-RemittingDouble-Blind MethodInternal medicinemedicineHumansAdverse effectCytokinePharmacologyPalmitoylethanolamideExpanded Disability Status ScaleTumor Necrosis Factor-alphabusiness.industryMultiple sclerosisN-acylethanolamineOleoylethanolamideAnandamideNAAAmedicine.diseaseAmides030104 developmental biologychemistryNeurology (clinical)business030217 neurology & neurosurgeryNeurotherapeutics
researchProduct

Probing human beta1- and beta2 -adrenoceptors with domain-specific fusion protein antibodies.

1997

In order to generate antibodies suitable for immunological studies on beta-adrenoceptors constitutively expressed at low levels in cells or tissues we have produced fusion proteins of the amino- and carboxy-terminus, and the second extracellular loop of the human beta 1- or beta 2-adrenoceptors with bacterial glutathione-S-transferase in E. coli. Rabbit antibodies raised against these fusion proteins strongly reacted with intact human beta 1- or beta 2-adrenoceptors in a subtype- and domain-specific manner. Antibodies directed against the second extracellular loop of the beta 1-adrenoceptor reacted stronger with non-denatured receptors and decreased the affinity of the 3H-labelled antagonis…

Recombinant Fusion ProteinsBlotting WesternEnzyme-Linked Immunosorbent AssayBiologyImmunofluorescenceProtein Structure SecondaryAntibodiesRadioligand AssayAntibody SpecificitymedicineExtracellularAnimalsHumansAvidityReceptorFluorescent Antibody Technique IndirectPharmacologymedicine.diagnostic_testMolecular biologyFusion proteinPrimary and secondary antibodiesPrecipitin TestsBlotMicroscopy FluorescenceBiochemistrybiology.proteinRabbitsReceptors Adrenergic beta-2AntibodyReceptors Adrenergic beta-1European journal of pharmacology
researchProduct

Myocardial and Peripheral Lymphocytic Transcriptomic Dissociation of β-adrenoceptors and G Protein–coupled Receptor Kinases in Heart Transplantation

2009

Background The genetic expression of adrenergic receptors plays an important pathophysiologic role in heart failure. G protein–coupled receptor kinases (GRKs) desensitize the β-receptor to catecholaminergic stimulation. It has been suggested that their mRNA expression in peripheral lymphocytes could mirror the changes in their myocardial expression in the failing heart, but this relationship between the myocyte and lymphocyte has not been studied in heart transplantation (HT). The objective of this study was to analyze adrenergic receptor and GRK mRNA expression in myocardium and lymphocytes and their correlation. Methods Twenty-three HT patients without evidence of acute rejection or echoc…

AdultPulmonary and Respiratory Medicinemedicine.medical_specialtyAdrenergic receptorBiopsymedicine.medical_treatmentLymphocyteInternal medicineReceptors Adrenergic betamedicineHumansLymphocytesRNA MessengerReceptorHeart transplantationTransplantationG protein-coupled receptor kinasebiologybusiness.industryGene Expression ProfilingMyocardiumBeta adrenergic receptor kinaseHeartMiddle AgedG-Protein-Coupled Receptor Kinasesmedicine.diseaseTransplantationEndocrinologymedicine.anatomical_structureHeart failurebiology.proteinHeart TransplantationSurgeryReceptors Adrenergic beta-2Receptors Adrenergic beta-1Cardiology and Cardiovascular MedicinebusinessThe Journal of Heart and Lung Transplantation
researchProduct

Anti-inflammatory and cognitive effects of interferon-β1a (IFNβ1a) in a rat model of Alzheimer’s disease

2018

Background: Aβ 1-42 peptide abnormal production is associated with the development and maintenance of neuroinflammation and oxidative stress in brains from Alzheimer disease (AD) patients. Suppression of neuroinflammation may then represent a suitable therapeutic target in AD. We evaluated the efficacy of IFNβ1a in attenuating cognitive impairment and inflammation in an animal model of AD. Methods: A rat model of AD was obtained by intra-hippocampal injection of Aβ 1-42 peptide (23 μg/2 μl). After 6 days, 3.6 μg of IFNβ1a was given subcutaneously (s.c.) for 12 days. Using the novel object recognition (NOR) test, we evaluated changes in cognitive function. Measurement of pro-inflammatory or …

0301 basic medicineTime Factorsmedicine.medical_treatmentHippocampusCell CountPharmacologymedicine.disease_causeHippocampuslcsh:RC346-429Superoxide Dismutase-10302 clinical medicineNeuroinflammationNF-kBMicrogliaGeneral NeuroscienceMicrofilament ProteinsROSPro-inflammatory cytokineIFNβ1amedicine.anatomical_structureCytokineNeurologyIL-10CytokinesFemalemedicine.symptomAlzheimer's diseaseInterferon beta-1aPro-inflammatory cytokinesImmunologyAβ 1-42InflammationProinflammatory cytokine03 medical and health sciencesCellular and Molecular NeuroscienceHippocampuAlzheimer DiseaseGlial Fibrillary Acidic ProteinmedicineAnimalsAβ1-42Rats WistarSODMaze Learninglcsh:Neurology. Diseases of the nervous systemNeuroinflammationInflammationAmyloid beta-PeptidesNeuroscience (all)Superoxide Dismutasebusiness.industryResearchCalcium-Binding ProteinsRecognition Psychologymedicine.diseasePeptide FragmentsRatsDisease Models Animal030104 developmental biologyLipid PeroxidationCognition DisordersReactive Oxygen Speciesbusiness030217 neurology & neurosurgeryOxidative stressJournal of Neuroinflammation
researchProduct

MRI activity and neutralising antibody as predictors of response to interferon beta treatment in multiple sclerosis

2008

Objective: To prospectively validate MRI activity and neutralising anti-interferon antibody (NAb) during the first 6 months of interferon β treatment as response indicators in multiple sclerosis (MS). Methods: Patients with relapsing–remitting MS were followed during the first 2 years of treatment. Neurological assessments were performed every 3 months or when a relapse was suspected. MRI scans performed at baseline and at 3, 4, 5 and 6 months after the start of treatment were assessed centrally for disease activity: new T2 or gadolinium enhancing T1 lesions. NAb were assessed using the MxA protein assay; positivity was defined as two consecutive titres ⩾20 NU/ml. We evaluated the predictiv…

MaleNeutralising antibodyMULTICENTERPLACEBO-CONTROLLED TRIALGUIDELINESGastroenterologyDOUBLE-BLINDInterferon βMAGNETIC-RESONANCEProspective StudiesNeurologic ExaminationbiologyBrainIMPAIRMENTMiddle AgedPredictive valueMagnetic Resonance ImagingRecombinant ProteinsPsychiatry and Mental healthTreatment OutcomeSettore MED/26 - NeurologiaFemaleAntibodyInterferon beta-1bAdultmedicine.medical_specialtyDIAGNOSTIC-CRITERIAInjections SubcutaneousAntibodiesDrug Administration ScheduleDisease activityMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicNeutralization TestsInternal medicinemedicineHumansInterferon betabusiness.industryMultiple sclerosisDISABILITYMSInterferon-betamedicine.diseaseConfidence intervalSurgerybiology.proteinSurgeryNeurology (clinical)businessFollow-Up Studies
researchProduct

Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of th…

2013

ObjectiveTo assess the effects of subcutaneous (sc) interferon (IFN) -1a on cognition over 5 years in mildly disabled patients with relapsing-remitting multiple sclerosis (RRMS).MethodsPatients aged 18-50 years with RRMS (Expanded Disability Status Scale score ≤4.0) who had completed the 3-year COGIMUS study underwent standardized magnetic resonance imaging, neurological examination, and neuropsychological testing at years 4 and 5. Predictors of cognitive impairment at year 5 were identified using multivariate analysis.ResultsOf 331 patients who completed the 3-year COGIMUS study, 265 participated in the 2-year extension study, 201 of whom (75.8%; sc IFN β-1a three times weekly: 44 µg, n = …

AdultMalemedicine.medical_specialty5 year follow upMultiple SclerosisAdolescentScienceInjections SubcutaneousBrain damageYoung AdultInterferonRecurrenceInternal medicinemedicineHumansIn patientYoung adultCognitive impairmentSex CharacteristicsMultidisciplinarymedicine.diagnostic_testbusiness.industryMultiple sclerosisQRMultiple Sclerosis Subcutaneous interferon β-1a cognitive impairmentMagnetic resonance imagingInterferon-betamedicine.diseaseTreatment OutcomeImmunologyMedicineFemaleSettore MED/26 - Neurologiamedicine.symptomSafetybusinessCognition DisordersInterferon beta-1amedicine.drugResearch ArticleFollow-Up Studies
researchProduct

Ischemic stroke increases heart vulnerability to ischemia-reperfusion and alters myocardial cardioprotective pathways

2018

Background and Purpose— For years, the relationship between cardiac and neurological ischemic events has been limited to overlapping pathophysiological mechanisms and common risk factors. However, acute stroke may induce dramatic changes in cardiovascular function. The aim of this study was to evaluate how prior cerebrovascular lesions affect myocardial function and signaling in vivo and ex vivo and how they influence cardiac vulnerability to ischemia-reperfusion injury. Methods— Cerebral embolization was performed in adult Wistar male rats through the injection of microspheres into the left or right internal carotid artery. Stroke lesions were evaluated by microsphere counting, tissue sta…

Cardiac function curveMalemedicine.medical_specialtySympathetic nervous systemGrowth Differentiation Factor 15Myocardial ischemiaNitro-oxidative stressHeart VentriclesIschemiaMyocardial Infarction030204 cardiovascular system & hematologyContractility03 medical and health sciences0302 clinical medicine[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemIn vivoInternal medicinemedicineAnimalsRats WistarStrokeIschemic StrokeAdvanced and Specialized Nursingbusiness.industryMyocardiumBrainIsolated Heart PreparationHeartmedicine.diseaseRatsStrokeAutonomic nervous systemOxidative Stressmedicine.anatomical_structureEchocardiographyNitrosative StressReperfusion InjuryCardiologyNeurology (clinical)Disease SusceptibilityReceptors Adrenergic beta-1Cardiology and Cardiovascular Medicinebusiness030217 neurology & neurosurgeryEx vivoAutonomic nervous system Subject terms: Ischemia
researchProduct

Quality of life, depression and fatigue in mildly disabled patients with relapsing–remitting multiple sclerosis receiving subcutaneous interferon bet…

2011

Background: The precise relationships among quality of life, depression, fatigue and cognitive impairment in multiple sclerosis (MS) are complex and poorly understood. Objective: To assess the effects of subcutaneous interferon beta-1a on quality of life, depression and fatigue over 3 years in the COGIMUS study, and to examine the relationship between these outcomes and baseline cognitive status. Methods: COGIMUS was an observational 3-year trial assessing cognitive function in 459 patients with relapsing–remitting MS treated with subcutaneous interferon beta-1a. Results: In total, 331 patients completed the study (168 received interferon beta-1a, 44 µg subcutaneously three times weekly, a…

AdultMaleQuality of lifeLongitudinal studymedicine.medical_specialtyInjections Subcutaneousmultiple sclerosisRelapsing-Remitting Multiple SclerosisInterferon beta 1aYoung AdultMultiple Sclerosis Relapsing-RemittingAdjuvants ImmunologicQuality of lifeInternal medicinemedicineHumansYoung adultFatigueDepression (differential diagnoses)AgedDepressionbusiness.industryCognitive function; Depression; Fatigue; Interferon beta 1a; Longitudinal study; Quality of life; Relapsing-Remitting Multiple SclerosisMultiple sclerosisCognitive disorderInterferon beta-1aInterferon-betaMiddle Agedmedicine.diseaseClinical trialNeurologyPhysical therapymultiple sclerosis cognition interferon betaFemaleSettore MED/26 - NeurologiaCognitive functionNeurology (clinical)Longitudinal studyCognition DisordersbusinessInterferon beta-1amedicine.drugMultiple Sclerosis Journal
researchProduct